India Funding: Renewables & Biotech Deals

India's innovation engine is firing on all cylinders, with significant capital injections bolstering key sectors. In a notable display of investor confidence, GPS Renewables has secured a substantial Rs 635 crore (approximately $66 million) in its Series C funding round. This significant capital infusion underscores the growing momentum in India's clean energy transition, a sector projected for robust expansion driven by government initiatives and increasing corporate sustainability goals.

The funding for GPS Renewables was a multi-faceted affair. PixelSky Capital spearheaded the equity tranche with a Rs 125 crore investment, joined by Spectrum Impact Family Office. Further bolstering its financial standing, the company's asset-holding platform, Arya, attracted Rs 200 crore from a prominent Korean conglomerate, building on an earlier Rs 310 crore commitment from Sojitz Corporation. With an annual revenue nearing Rs 1,000 crore and a workforce exceeding 800, GPS Renewables is strategically positioned, managing over 30 operational projects and holding strong visibility for more than 200 compressed biogas (CBG) projects in collaboration with major oil marketing companies.

Simultaneously, the life sciences sector is experiencing its own surge of investment. Immuneel Therapeutics, a pioneering cancer-focused biotechnology firm, has successfully closed its Series B funding, raising over Rs 100 crore (more than $10.5 million). This round saw participation from a distinguished group of investors including Singularity AMC, Rainmatter by Zerodha, and several high-net-worth individuals (HNIs). Crucially, existing backers such as Kiran Mazumdar-Shaw, Eight Roads Ventures, and F-Prime Capital also reinvested, signaling continued belief in the company's therapeutic advancements.

Founded in 2018, Immuneel Therapeutics has recently achieved a significant milestone with the commercialization of Qartemi, recognized as India's first approved CAR-T therapy for specific types of lymphoma and leukemia. The newly acquired capital will be instrumental in scaling up its Good Manufacturing Practice (GMP) facilities, accelerating the market penetration of its innovative treatments, and facilitating expansion into the Asia Pacific and Middle East regions. This development highlights the increasing sophistication and global competitiveness of India's biotech industry.

Beyond these major rounds, other companies are also making strides. Wholeleaf, a startup specializing in cannabinoid-based pain therapeutics, is reportedly in advanced discussions to raise Rs 7.5 crore from investors IPV and Benzai 10 Capital. The company, which has already garnered support from notable figures like Aman Gupta, Kanika Tekriwal, and Namita Thapar, boasts an annual recurring revenue of Rs 18 crore and an expanding retail footprint.

In the broader business ecosystem, cloud kitchen operator Curefoods has reportedly paused its initial public offering plans amidst prevailing market uncertainties, a move mirroring decisions by other prominent digital enterprises. Meanwhile, the used car marketplace Cars24 has strengthened its board with the appointment of Jayesh Sanghrajka, the CFO of Infosys, as an independent director, signaling readiness for its own potential public listing. Edtech firm Klassroom has also secured in-principle approval from the Bombay Stock Exchange for its SME IPO, indicating a healthy pipeline of companies preparing for public markets.